reports
- Jacob Mekhael
Galapagos Appoints Aaron Cox as new CFO
Galapagos announced the appointment of Aaron Cox as CFO, effective 7 July 2025. Most recently, he served as Executive VP and CFO at Horizon Therapeutics. Aaron replaces Thad Huston, who joined Galapagos as CFO in 2023. With plans to explore strategic options for the cell therapy business, as well as plans to utilise the €3.3b cash (as of 1Q25) to build a new pipeline through business development, Aaron's network and experience in deal making will be key to Galapagos' strategy going forward. We r...
- Hilde Van Boxstael
- Jacob Mekhael
- Wim Lewi
Galapagos benoemt Aaron Cox als Chief Financial Officer
Galapagos benoemt Aaron Cox als Chief Financial Officer Voormalig CFO van Horizon vervoegt Galapagos met diepgaande expertise in internationale bedrijfsfinanciering, fusies en overnames, bedrijfsontwikkeling en strategisch leiderschap Mechelen, België; 23 juni 2025, 07:30 CET; gereglementeerde informatie - voorwetenschap - Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag de benoeming aan van de heer Aaron Cox als Chief Financial Officer, met ingang van 7 juli 2025. De heer Cox volgt de heer Thad Huston op, die tot 31 juli 2025 bij het bedrijf zal blijven om een soepele overdracht t...
Galapagos Appoints Aaron Cox as Chief Financial Officer
Galapagos Appoints Aaron Cox as Chief Financial Officer Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Mr. Aaron Cox as Chief Financial Officer, effective July 7, 2025. Mr. Cox succeeds Mr. Thad Huston, who will remain with the company through July 31, 2025, to ensure a smooth transition of responsibilities.Aaron brings more than two ...
Galapagos NV: 1 director
A director at Galapagos NV bought 5,129 shares at 28.300EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
- Jacob Mekhael
Galapagos GLPG5101 phase 1/2 r/r iNHL cohort differentiates with high ...
Galapagos presented new data from the ongoing Phase 1/2 (ATALANTA-1) study of GLPG5101 (CD19 CAR-T) at the International Conference on Malignant Lymphoma (ICML). Results from the r/r iNHL cohort (FL and MZL) showed a high complete response rate of 97%, higher than Yescarta's 75% CR rate (79% in FL, 75% in MZL) in the same patient population in the phase 2 (ZUMA-5) trial. Safety continues to be a differentiator with only 1 grade 3 ICANS (vs. 19% grade = 3 with Yescarta). All in all, a supportive ...
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 ...
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101 Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CAR-T cells, and 93% were treated within seven days of manufacturing GLPG5101 demonstrated promising efficacy with durable CAR-T cell persistence and a favorable safety profile, including a 97% complete response rate, 100% MRD negativity in evaluable patients, su...
Galapagos presenteerde nieuwe gegevens op ICML 2025 van Cohort 3 van d...
Galapagos presenteerde nieuwe gegevens op ICML 2025 van Cohort 3 van de ATALANTA-1 studie bij patiënten met recidief/refractair indolent NHL, en toonde hoge complete respons- en MRD-negativiteitspercentages aan met de CAR-T-kandidaat GLPG51 Van de 34 patiënten die werden ingeschreven in Cohort 3 van de ATALANTA-1 fase 1/2-studie, ontvingen er 32 GLPG5101; 94% kreeg verse CAR T-cellen toegediend, en 93% werd behandeld binnen zeven dagen na productie GLPG5101 toonde veelbelovende werkzaamheid met een langdurige CAR T-cel persistentie en een gunstig veiligheidsprofiel, waaronder 97% complete...
- Jacob Mekhael
Galapagos Updated NHL phase 1/2 GLPG5101 data at EHA shows decentralis...
Galapagos will present new data from the ongoing Phase 1/2 (ATALANTA-1) study of GLPG5101 (CD19 CAR-T) at the European Hematology Association (EHA) Congress, being held 12-15 June. The results demonstrate POC for a 7 day vein-vein de-centralised CAR-T manufacturing process. Combined with the previously reported safety differentiation, we believe this could support strategic discussions as the company is exploring such options for its cell therapy business. We reiterate our Buy rating and € 37 TP...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Thomas Vranken
- Wim Lewi
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighti...
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities Of the 64 patients enrolled, 61 received treatment, resulting in a 5% attrition rate, significantly lower than industry benchmarks. 95% of patients were infused with fresh, stem-like early memory CD19 CAR-T cell...
Galapagos zal nieuwe ATALANTA-1 CAR-T data presenteren op EHA 2025, me...
Galapagos zal nieuwe ATALANTA-1 CAR-T data presenteren op EHA 2025, met lage toxiciteit en snelle, gedecentraliseerde toediening van vers, early-memory-verrijkt GLPG5101 bij R/R NHL Gegevens uit de lopende ATALANTA-1 fase 1/2-studie bij een zwaar voorbehandelde patiëntengroep met recidief/refractair non-Hodgkinlymfoom (R/R NHL) tonen lage percentages van hooggradige toxiciteiten aan Van de 64 ingeschreven patiënten werden er 61 behandeld, wat resulteerde in een uitvalpercentage van 5%, aanzienlijk lager dan de benchmarks. 95% van de patiënten werd geïnfuseerd met verse,...
- Michiel Declercq
- Wim Hoste
- Guy Sips
Miko Facing profit pressure amid rising coffee prices and bonus disput...
We updated our model after Miko, the Turnhout-based coffee producer, delivered two key warnings during its recent shareholders' meeting. First, the company is struggling to fully pass on the steep rise in coffee bean prices to its customers. Second, a €5m earn-out bonus from the 2021 sale of its packaging division Miko Pac is being disputed by the buyer, Paccor. As a result we lower our DCF-based TP from €67 to €60 but maintain our Accumulate rating.
Galapagos Creates New Subscription Right Plan
Galapagos Creates New Subscription Right Plan Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new subscription right plan. On May 27, 2025, the Board of Directors of Galapagos approved “Subscription Right Plan 2025 (A)”, intended for personnel of the Company, within the framework of the authorized capital. Under this subscription right plan, 925,000 subscription rights were created, subject to acceptance, for senior management compensation p...
Galapagos creëert nieuw inschrijvingsrechtenplan
Galapagos creëert nieuw inschrijvingsrechtenplan Mechelen, België; 27 mei 2025, 22:30 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) kondigt vandaag aan dat haar Raad van Bestuur 925.000 inschrijvingsrechten heeft gecreëerd onder een nieuw inschrijvingsrechtenplan. De Raad van Bestuur van Galapagos heeft op 27 mei 2025 “Inschrijvingsrechtenplan 2025 (A)”, bestemd voor personeel van de Vennootschap, goedgekeurd binnen het kader van het toegestaan kapitaal. Onder dit inschrijvingsrechtenplan werden 925.000 inschrijvingsrechten gecreëerd in het kader voor beloningen...
- Felix Fischer
Europe HY Trade Book - May 2025 - Lucror Analytics
The Europe HY Trade Book for May 2025 includes current trade recommendations drawn from our European HY coverage universe, along with relative-value scatter plots and tables by industry. We also discuss the US tariff situation and key related impacts.
SCHP SECHE ENVIRONNEMENT
PFD PREMIER FOODS PLC
AMS AMS AG
CO CASINO GUICHARD-PERRACHON SA
VK VALLOUREC SA
TLW TULLOW OIL PLC
EO FAURECIA SA
105I SAPPI LIMITED
TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
LBTYA LIBERTY GLOBAL PLC CLASS A
CSTM CONSTELLIUM SE CLASS A
CCK CROWN HOLDINGS INC.
RXL REXEL SA
DBG DERICHEBOURG SA
725180 STADA ARZNEIMITTEL AG
NOKIA NOKIA OYJ
TNET TELENET GROUP HOLDING NV
TUI1 TUI AG
NEX NEXANS SA
VED VEDANTA RESOURCES PLC
VCP VICTORIA PLC
AF AIR FRANCE-KLM SA
BBD.B BOMBARDIER INC. CLASS B
SYNT SYNTHOMER PLC
INTRUM INTRUM AB
888 888 HOLDINGS PLC
IPF INTERNATIONAL PERSONAL FINANCE PLC
ENQ ENQUEST PLC
EDR EDREAMS ODIGEO SA
TC1 TELE COLUMBUS AG
9984 SOFTBANK GROUP CORP.
103M SASOL LIMITED
TIT TELECOM ITALIA S.P.A.
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
TGS TGS-NOPEC GEOPHYSICAL COMPANY ASA
TALK TALKTALK TELECOM GROUP PLC
TATAMOTORS TATA MOTORS LIMITED
PL8 PLAYTECH PLC
ARW ARROW GLOBAL GROUP PLC
NEMAKA NEMAK S.A.B. DE C.V.
SPIE SPIE SA
CEXA CEMEX SAB DE CV (ADR)
ARD ARDAGH GROUP S.A. CLASS A
PFL PFLEIDERER GROUP SA
DIGI DIGI COMMUNICATIONS NV
CDR CODERE S.A.
GAME GAMENET GROUP SPA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS PLC
AXA AXACTOR SE
BORR SECURITAS DIRECT AB CL B
BORR DRILLING LTD
- Jan Frederik Slijkerman
1Q25 Results: Telenet, VodafoneZiggo, Virgin Media O2/Delays until the...
The 1Q25 earnings reports of VodafoneZiggo, Telenet and Virgin Media O2[de] were soft. When compared to 4Q24, leverage deteriorated across the board in 1Q25, while all companies lost broadband customers. We were especially disappointed by the weaker outlook for VodafoneZiggo. Although all businesses have their intrinsic strengths, there are challenges, as described below, and our conviction to buy or sell the notes is low. We see limited value in current spreads. Nevertheless, there is still ups...
- Jacob Mekhael
EHA abstracts Autolus, Galapagos, MaaT
The abstracts for presentations at EHA (12-15 June) became available yesterday during the day (here). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (long-term findings and predictors of sustained remission for Aucatzyl in r/r adult ALL, as well as age stratified outcomes), Galapagos (more data and follow up from its decentralised CAR-T program) and MaaT (additional data from ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.